ResearchNXTC

NXTC: FY25 Deep Dive

Ddrillr ResearchOriginal research

Published Sep 3, 20261 min read

Summary

NextCure FY25 at $0M. NI $-56M; EPS $-19.65.

FY25 revenue $0M; OI $-58M; NI $-56M; EPS $-19.65.

NextCure FY25 (Dec 31, 2025) at $0M revenue. OpInc $-58M; NI $-56M; EPS $-19.65. Biotech.